Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

NCT01717638 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

805

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Disease
Meningococcal Meningitis

Interventions

BIOLOGICAL: 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
BIOLOGICAL: 2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine

Sponsor

Novartis Vaccines